Pharmacotherapy for obesity

被引：11

作者：

Hensrud, DD

机构：

[1] Mayo Clin & Mayo Fdn, Div Prevent Med, Rochester, MN 55905 USA

[2] Mayo Clin & Mayo Grad Sch Med, Div Prevent Med, Rochester, MN 55905 USA

[3] Mayo Clin & Mayo Grad Sch Med, Div Metab Endocrinol & Nutr, Rochester, MN 55905 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 2000年 / 84卷 / 02期

关键词：

D O I：

10.1016/S0025-7125(05)70231-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article discusses former and current medications used to treat obesity, reviews efficacy and safety data for current medications, and suggests clinical guidelines for their use.

引用

页码：463 / +

页数：15

共 36 条

[31]

Stock MJ, 1997, INT J OBESITY, V21, pS25

[32] LONG-TERM WEIGHT CONTROL STUDY .1. (WEEKS 0 TO 34) - THE ENHANCEMENT OF BEHAVIOR-MODIFICATION, CALORIC RESTRICTION, AND EXERCISE BY FENFLURAMINE PLUS PHENTERMINE VERSUS PLACEBO [J].

WEINTRAUB, M ;

SUNDARESAN, PR ;

MADAN, M ;

SCHUSTER, B ;

BALDER, A ;

LASAGNA, L ;

COX, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :586-594

[33] An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo [J].

Weissman, NJ ;

Tighe, JF ;

Gottdiener, JS ;

Gwynne, JT .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) :725-732

[34]

WONG DT, 1975, J PHARMACOL EXP THER, V193, P804

[35]

Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907

[36] RETROSPECTIVE POPULATION-BASED ANALYSIS OF THE DOSE-RESPONSE (FECAL FAT EXCRETION) RELATIONSHIP OF ORLISTAT IN NORMAL AND OBESE VOLUNTEERS [J].

ZHI, J ;

MELIA, AT ;

GUERCIOLINI, R ;

CHUNG, J ;

KINBERG, J ;

HAUPTMAN, JB ;

PATEL, IH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) :82-85

← 1 2 3 4 →